Search clinical trials for: Riociguat (BAY63-2521)

Total 331 results

Bayer

Completed

Single Dose Study in Patients With Chronic Obstructive Pulmonary Disease (COPD) Associated Pulmonary Hypertension.

Pulmonary Disease, Chronic Obstructive | Hypertension, Pulmonary

Germany
Bayer

Completed

Relative Bioavailability and Food Effect Study

Pharmacology, Clinical

Germany
Bayer

Completed

BAY63-2521:Long-term Extension Study in Patients With Pulmonary Arterial Hypertension (PATENT-2)

Hypertension, Pulmonary

Belgium, France, China, Turkey, Portugal, Taiwan, Japan, Singapore, United States, Argentina, Switzerland, Mexico, Austria, Thailand, Canada, Denmark, Germany, Russian Federation, Australia, Italy, Korea, Republic of, Sweden, Poland, United... and more
Bayer

Completed

EXPERT, EXPosurE Registry RiociguaT in Patients With Pulmonary Hypertension (EXPERT)

Hypertension, Pulmonary

Turkey, Austria, Czechia, Russian Federation, Slovakia, Switzerland, Italy, Germany, United Kingdom, France, Belgium, Canada, Colombia, Greece, Luxembourg, Netherlands, Spain, Taiwan, Denmark, Sweden, Argentina, Portugal, Saudi Arabia, Austral... and more
Bayer

Terminated

A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Diastolic Dysfunction (DILATE)

Hypertension, Pulmonary | Ventricular Dysfunction, Left

Austria, Germany, Czech Republic
Bayer

Completed

A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH. (CHEST-1)

Pulmonary Hypertension

Belgium, France, Spain, Turkey, Portugal, Taiwan, Japan, United States, Switzerland, Korea, Republic of, Austria, Canada, China, Denmark, Germany, Russian Federation, Mexico, Argentina, Netherlands, Italy, Poland, United Kingdom, Au... and more
Bayer

Completed

Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis

Scleroderma, Systemic

Netherlands, Belgium, United States, Australia, Hungary, United Kingdom, Canada, Germany, Switzerland, France, Italy, Japan, New Zealand, Turkey, Czechia
Bayer

Completed

Relative Bioavailability Study

Healthy Volunteers

Germany
Bayer

Completed

An Open Multiple Dose Titration Study In Patients With Pulmonary Hypertension

Hypertension, Pulmonary

Germany
Bayer

Completed

Prospective, Non-interventional, Multi-center, Post-authorization Safety Study of Riociguat for Pulmonary Arterial Hypertension (PAH) (JPMS-PAH)

Hypertension, Pulmonary

Japan
Bayer

Completed

Riociguat Clinical Effects Studied in Patients With Insufficient Treatment Response to Phosphodiesterase-5 Inhibitor (RESPITE)

Hypertension, Pulmonary

Belgium, United States, Switzerland, Canada, France, Germany, Italy, United Kingdom, Czechia
Bayer

Completed

A Study to Understand the Treatment Patterns in Patients With Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension During a Switch of Treatment to Adempas in Real-life Clinical Practice (CAPTURE)

Hypertension, Pulmonary

Japan, Germany, Sweden, Colombia, Turkey, Belgium, Canada
Bayer

Recruiting

A Long-term Extension Study of Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension. (RIALTO)

Hypertension, Pulmonary

France, Italy, Korea, Republic of, Poland, Thailand
Bayer

Active, not recruiting

Impact of Multiple Doses of BAY63-2521 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Interstitial Lung Disease (ILD) Associated Pulmonary Hypertension (PH)

Hypertension, Pulmonary

Germany
Bayer

Completed

BAY63-2521 - Long-term Extension Study in Patients With Chronic Thromboembolic Pulmonary Hypertension (CHEST-2)

Pulmonary Hypertension

Belgium, France, Spain, Turkey, Portugal, Taiwan, Japan, United States, Switzerland, Korea, Republic of, Austria, Canada, China, Denmark, Germany, Mexico, Russian Federation, Argentina, Italy, Poland, Australia, Brazil, Czechia, United... and more
Bayer

Terminated

Hemodynamic and Echocardiographic Assessment of Riociguat Effects on Myocardial Wall Contractility and Relaxation Kinetics (HEARTWORK)

Hypertension, Pulmonary | Ventricular Dysfunction, Left

United States
Bayer
Merck Sharp & Dohme LLC

Active, not recruiting

Riociguat in Children With Pulmonary Arterial Hypertension (PAH) (PATENT-CHILD)

Hypertension, Pulmonary

Germany, Turkey, Japan, Italy, Mexico, Poland, Hungary, Taiwan, Colombia
Bayer

Completed

Prospective, Non-interventional, Multi-center Post-authorization Safety Study of Riociguat for Chronic Thromboembolic Pulmonary Hypertension (CTEPH ) (JPMS-CTEPH)

Hypertension, Pulmonary

Japan
Bayer
Xcenda, LLC

Active, not recruiting

A Study to Learn About How Well Riociguat Works, How Safe it is and How it is Used Under Real World Conditions in Patients in the United States Who Are Receiving Riociguat for High Blood Pressure in the Arteries That Carry Blood From the Heart to the Lungs (Pulmonary Arterial Hypertension, PAH) (ROAR)

Pulmonary Arterial Hypertension

United States, Puerto Rico
Bayer

Completed

A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH) (PATENT-1)

Pulmonary Hypertension

Belgium, France, Spain, China, United States, Turkey, New Zealand, Portugal, Taiwan, Japan, Australia, Singapore, Argentina, Sweden, Switzerland, Mexico, Austria, Thailand, Canada, Denmark, Germany, Israel, Russian Federation, Italy, Korea... and more
Bayer

Completed

Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION)

Hypertension, Pulmonary

United States, Puerto Rico
Bayer

Completed

Digital Flow Enhancement in Raynaud's Phenomenon With an sGC (Soluble Guanylate Cyclase) Stimulator (DIGIT)

Raynaud Disease

Germany
Bayer

Active, not recruiting

A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction (LEPHT)

Hypertension, Pulmonary | Ventricular Dysfunction, Left

Belgium, France, China, Spain, Japan, United States, Singapore, Canada, Switzerland, Austria, Denmark, Germany, Italy, Australia, Czechia, Netherlands, Poland, United Kingdom
Bayer

Completed

Interaction Study in Patients With Pulmonary Hypertension and Stable Treatment of Sildenafil 20 mg TID

Hypertension, Pulmonary

Germany
Bayer

No longer available

Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH) (EAS)

Hypertension, Pulmonary

Belgium, France, Italy, Spain, United States, Switzerland, Turkey, Portugal, Canada, Sweden, Germany, Austria, Denmark, Mexico, Russian Federation, Colombia, United Kingdom, Netherlands, Japan, Czech Republic
Bayer

Terminated

Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP) (RISE-IIP)

Idiopathic Interstitial Pneumonias / Hypertension,Pulmonary

Belgium, Israel, Spain, United States, Switzerland, New Zealand, Greece, Portugal, Japan, Argentina, Canada, Denmark, France, Germany, Russian Federation, Turkey, Colombia, Saudi Arabia, Australia, Italy, United Kingdom
Bayer

Withdrawn

Coronary Vasomotor Response After Riociguat Exposure (CORONARIES)

Coronary Artery Disease

United States
Bayer

Completed

Effect of Riociguat on Bone Metabolism

Pharmacology, Clinical

Germany
Bayer
Merck Sharp & Dohme LLC

Terminated

Early Signs of Efficacy Study With Riociguat in Adult Homozygous Delta F508 Cystic Fibrosis Patients

Cystic Fibrosis

Germany, United States, France, Canada, Belgium, Netherlands, United Kingdom
Bayer

Completed

Evaluation of the Pharmacodynamic Effect of the Combination of Sildenafil and Riociguat on Blood Pressure and Other Safety Parameters. (PATENT PLUS)

Pulmonary Hypertension

Spain, New Zealand, Germany, Austria, United States, Poland, Italy, United Kingdom, Czech Republic
Bayer

Completed

Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy (REPLACE)

Pulmonary Arterial Hypertension

Belgium, France, Spain, Portugal, Turkey, United States, Germany, Korea, Republic of, Mexico, Austria, Canada, Denmark, Poland, Italy, Greece, Taiwan, Czechia, Netherlands, Japan, Brazil, United Kingdom
Bayer

Completed

Study on the Safety of BAY 63-2521, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given as a Single Oral Dose of 1 mg Tablet in Participants With Renal Impairment and Healthy Participants Matched for Age-, Gender-, and Weight

Clinical Pharmacology

Germany
Danish Headache Center

Not yet recruiting

Effect of Riocigaut on Migraine Attack Induction and Cerebral Vasodilation in Migraine Patients.

Migraine Without Aura

Denmark
Bayer

Completed

Study on the Safety of BAY 63-2521, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given as a Single Oral Dose of 1 mg Tablet in Participants With Impaired Liver Function and Healthy Participants Matched for Age-, Gender-, and Weight

Clinical Pharmacology

Germany
International CTEPH Association

Terminated

Riociguat in Patients With Operable CTEPH Prior to Pulmonary Endarterectomy (PEA Bridging Study)

Chronic Thromboembolic Pulmonary Hypertension | CTEPH

Germany, United States, United Kingdom, France
Bayer

Completed

Microgynon Riociguat Drug Interaction Study in Healthy Postmenopausal Women

Drug Interactions

Germany
Merck Sharp & Dohme LLC

Completed

A Single and Multiple-Dose Study of MK-8521 in Healthy and Obese Males (MK-8521-002)

Type 2 Diabetes Mellitus
Danish Headache Center

Completed

Effect of Riocigaut on Cerebral Vasodilation and Headache Induction in Healthy Volunteers

Headache

Denmark
National Hospital Organization Okayama Medical...
Bayer Yakuhin, Ltd.

Recruiting

THERAPY-HYBRID-BPA Trial

Hypertension, Pulmonary

Japan
Humanis Saglık Anonim Sirketi

Completed

Bioequivalence Study of Riociguat 2.5 mg Film Coated Tablets and Adempas (Riociguat) 2.5 mg Film Coated Tablets

Pulmonary Arterial Hypertension

India
Bayer

Terminated

Use of Sorafenib and/or Regorafenib in Liver Cancer (Hepatocellular Carcinoma) Subsequent to Another Systemic First-line Treatment (SORAGO-HCC)

Hepatocellular Carcinoma

Germany
Heidelberg University
Merck Sharp & Dohme LLC

Recruiting

Efficacy and Safety of Riociguat in Incipient Pulmonary Vascular Disease as an Indicator for Early PAH (ESRA)

Systemic Sclerosis | Pulmonary Vascular Disorder | Primary Pulmonary Hypertension | Other Systemic Involvement of Connective Tissue

Austria, Germany, Italy, France, Switzerland
University of Calgary
Bayer

Unknown

Upfront Combination Pulmonary Arterial Hypertension Therapy

Pulmonary Hypertension

Canada
Assistance Publique - Hôpitaux de Paris
Bayer

Completed

Riociguat Versus Balloon Pulmonary Angioplasty in Non-operable Chronic thromboEmbolic Pulmonary Hypertension (RACE)

Chronic Thromboembolic Pulmonary Hypertension

France
University of Arizona

Unknown

Trial to Evaluate Parenteral Treprostinil and Riociguat on Right Ventriculo-vascular Coupling and Morphology in Those With Advanced PAH

Pulmonary Arterial Hypertension

United States
Bayer

Completed

An Observational Study, Called ROCURS, to Learn About COVID-19 Related Outcomes in People With Cancer Who Are Treated With Tyrosine Kinase Inhibitors (TKIs) Including Regorafenib or Sorafenib (ROCURS)

Coronavirus Disease 2019 (COVID-19) | SARS-CoV-2 Infection | Malignant Solid Tumors

United States
Bayer

Completed

Safety Study of BAY73-4506 in Patients With Hepatocellular Carcinoma

Carcinoma, Hepatocellular

Italy, Spain, Germany, Korea, Republic of
European Organisation for Research and Treatment...

Completed

ISIS 3521 in Treating Patients With Advanced, Unresectable, or Metastatic Non-small Cell Lung Cancer or Unresectable or Metastatic Melanoma

Lung Cancer | Melanoma (Skin)

France, Netherlands, Norway, Belgium, Switzerland, United Kingdom, Germany, Denmark, Austria
Bayer

No longer available

Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy (CONSIGN)

Colorectal Neoplasms

France, Belgium, Spain, United States, Canada, Switzerland, Germany, Russian Federation, Australia, Austria, Israel, Italy, Mexico, Netherlands, Norway, United Kingdom, Poland, Hungary, Denmark, Portugal, Finland, Sweden, Ireland, Greece and more
Novo Nordisk A/S

Terminated

A Multi-centre, Open Labelled, Multiple Dosing Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC 0172-2021 Administered Subcutaneously to Healthy Male Subjects and Haemophilia Subjects (explorer™2)

Healthy | Congenital Bleeding Disorder | Haemophilia A

Austria, Spain, United Kingdom, France, Germany

Search clinical trials for: Riociguat (BAY63-2521)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jamaica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations